As IL-2Rβγ was predominantly expressed in tumor-infiltrated CD8+ T and NK cells (Figure 1(B,D,F,H)), these results indicated that, as a target candidate, NKG2A might be more efficient than PD-1 for delivery of IL-2Rβγ agonist to tumor-infiltrated immune effector cells. The gene discussed is PDCD1; the disease is neoplasm.